No Data
No Data
Buy Rating Justified by Promising Efficacy and Safety Profile of Olema Pharmaceuticals' Drug Combination in Clinical Studies
Express News | HC Wainwright & Co. Reiterates Buy on Olema Pharmaceuticals, Maintains $30 Price Target
Promising Clinical Trial Results Bolster Buy Rating for Olema Pharmaceuticals
OPEN, BCRX and AWIN Among Pre-market Gainers
Olema Pharmaceuticals Announces Promising Breast Cancer Trial Results
Express News | Olema Oncology Announces Interim Results From Phase 1b/2 Palazestrant Study, Says 85% Clinical Benefit Rate Observed To Date Across All CBR-Eligible Patients